← Leaderboards
Reuben Lotan
University Of Texas Md Anderson Can Ctr
$1,675,909
Attributed
$1,675,909
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $316.7K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,878,461 · 7
By mechanism
P50$1,496,898 · 4
P01$1,381,563 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Scott M Lippman$54,535,308
- Jeffrey Nicholas Myers$13,165,599
- Xifeng Wu$28,679,533
- J. Jack Lee$12,331,191
- Rakesh Kumar$9,172,951
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisRetinoidsTissue /Cell CultureOral Pharyngeal NeoplasmPreneoplastic StateCell Growth RegulationCarcinogenesisHead /Neck NeoplasmCarcinogenesis InhibitorHuman SubjectChemopreventionAthymic MouseCancer PreventionDrug Screening /EvaluationHuman TissueNeoplasm /Cancer DiagnosisButyratesIn Situ HybridizationNeoplasm /Cancer TherapyProstaglandin Endoperoxide SynthaseCombination ChemotherapyNonsteroidal Antiinflammatory AgentOrgan CultureWestern Blottings
Grant awards (20)
TARGETING COX-2 AND EGFR SIGNALING IN ORAL CARCINOGENESIS$137,806
P01 · FY2008 · CA · contact PI
TARGETING COX-2 AND EGFR SIGNALING IN ORAL CARCINOGENESIS$316,731
P01 · FY2007 · CA · contact PI
TARGETING COX-2 AND EGFR SIGNALING IN ORAL CARCINOGENESIS$232,701
P01 · FY2006 · CA · contact PI
TARGETING COX-2 AND EGFR SIGNALING IN ORAL CARCINOGENESIS$227,326
P01 · FY2005 · CA
TARGETING COX-2 AND EGFR SIGNALING IN ORAL CARCINOGENESIS$221,066
P01 · FY2004 · CA
Core--Developmental research$0
P50 · FY2002 · CA
Targeting apoptosis pathways for therapy of head and neck cancer$0
P50 · FY2002 · CA
LUNG CANCER PREVENTION BY COX2 AND 5LOX INHIBITORS$0
P01 · FY2002 · CA
NUCLEAR RETINOIC ACID RECEPTORS IN HEAD/NECK CARCINOGENESIS &CHEMOPREVENTION$0
P01 · FY2002 · CA
NOVEL DIAGNOSIS AND THERAPY OF EARLY ORAL CANCERS$406,399
P50 · FY2001 · DE
NOVEL DIAGNOSIS AND THERAPY OF EARLY ORAL CANCERS$4,050
P50 · FY2001 · DE
CELL DIFFERENTIATION, GROWTH, AND APOPTOSIS IN ORAL CARCINOGENESIS$0
P50 · FY2001 · DE
NUCLEAR RETINOIC ACID RECEPTORS IN HEAD/NECK CARCINOGENESIS &CHEMOPREVENTION$0
P01 · FY2001 · CA
LUNG CANCER PREVENTION BY COX2 AND 5LOX INHIBITORS$0
P01 · FY2001 · CA
CELL DIFFERENTIATION, GROWTH, AND APOPTOSIS IN ORAL CARCINOGENESIS$0
P50 · FY2001 · DE
NOVEL DIAGNOSIS AND THERAPY OF EARLY ORAL CANCERS$789,128
P50 · FY2000 · DE
NUCLEAR RETINOIC ACID RECEPTORS IN HEAD/NECK CARCINOGENESIS &CHEMOPREVENTION$245,933
P01 · FY2000 · CA
CELL DIFFERENTIATION, GROWTH, AND APOPTOSIS IN ORAL CARCINOGENESIS$191,471
P50 · FY2000 · DE
CELL DIFFERENTIATION, GROWTH, AND APOPTOSIS IN ORAL CARCINOGENESIS$102,875
P50 · FY2000 · DE
NOVEL DIAGNOSIS AND THERAPY OF EARLY ORAL CANCERS$2,975
P50 · FY2000 · DE